EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025

Avnika B Amin, Jennifer P Collins, Xiaoyu Dong, Andrew J Leidner, Jamie Loehr, Charlotte A Moser, Lucy A McNamara

MMWR. Morbidity and Mortality Weekly Report · 2026

DOI: 10.15585/mmwr.mm7501a2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2026. Verfasst von Avnika B Amin und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Meningococcal Vaccines, Meningococcal Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningococcal disease is a serious bacterial infection caused by Neisseria meningitidis. Serogroups B, C, W, and Y cause the majority of cases of this disease in the United States. These serogroups are targeted by different meningococcal vaccines available in the United States. Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and two serogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer]) are licensed for use in the United States and recommended by CDC's Advisory Committee on Immunization Practices (ACIP). Indications for MenACWY and MenB vaccination have not changed since indications for their use were published in 2020. A pentavalent (serogroups A, B, C, W, and Y) meningococcal vaccine (MenABCWY) (MenACWY-TT/MenB-FHbp [Penbraya, Pfizer]) has been licensed and recommended for use since October 2023. On February 14, 2025, the Food and Drug Administration licensed a second pentavalent MenABCWY vaccine (MenACWY-CRM/MenB-4C [Penmenvy, GSK]) for prevention of invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y in persons aged 10-25 years, the same indication for which MenACWY-TT/MenB-FHbp is licensed. On April 16, 2025, ACIP recommended that MenACWY-CRM/MenB-4C may be used when both MenACWY and MenB are indicated at the same visit for 1) healthy persons aged 16-23 years (routine schedule) when shared clinical decision-making favors administration of MenB vaccine and 2) persons aged ≥10 years who are at increased risk for meningococcal disease (e.g., because of persistent complement deficiencies, complement inhibitor use, or functional or anatomic asplenia). Different manufacturers' serogroup B-targeting vaccines are not interchangeable; therefore, when MenACWY-CRM/MenB-4C is used, MenB-4C should be used for the other MenB doses. This report summarizes evidence considered for these recommendations and provides clinical guidance for the use of MenACWY-CRM/MenB-4C.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal VaccinesMeningococcal InfectionsHumansUnited StatesAdolescentChildAdvisory CommitteesAdultYoung AdultCenters for Disease Control and Prevention, U.S.Middle AgedMaleImmunization ScheduleVaccines, ConjugateAged

Substanzen

Meningococcal VaccinesMenACWYVaccines, Conjugate

Zitieren

APA

Amin, A. B., Collins, J. P., Dong, X., Leidner, A. J., Loehr, J., Moser, C. A., & McNamara, L. A. (2026). Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7501a2

Vancouver

Amin AB, Collins JP, Dong X, Leidner AJ, Loehr J, Moser CA, et al. Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025. MMWR. Morbidity and Mortality Weekly Report. 2026. doi:10.15585/mmwr.mm7501a2

BibTeX
@article{Amin2026,
  author = {Amin, Avnika B and Collins, Jennifer P and Dong, Xiaoyu and Leidner, Andrew J and Loehr, Jamie and Moser, Charlotte A and McNamara, Lucy A},
  title = {Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  year = {2026},
  doi = {10.15585/mmwr.mm7501a2}
}
Kostenlos starten →